Vumerity vs. Tysabri

• Are Vumerity and Tysabri the Same Thing?
• What Are Possible Side Effects of Vumerity?
• What Are Possible Side Effects of Tysabri?
• What Is Vumerity?
• What Is Tysabri?
• What Drugs Interact with Vumerity?
• What Drugs Interact with Tysabri?
• How Should Vumerity Be Taken?
• How Should Tysabri Be Taken?

Vumerity (diroximel fumarate) and Tysabri (natalizumab) are used to treat relapsing forms of multiple sclerosis (MS).

Tysabri is also used to treat moderate to severe Crohn's disease in adults. Tysabri is usually given after other Crohn's disease medications have been tried without successful treatment of this condition.

Vumerity and Tysabri belong to different drug classes. Vumerity is an immunomodulator and Tysabri is a monoclonal antibody.

Side effects of Vumerity and Tysabri that are similar include abdominal/stomach pain, diarrhea, and skin rash.

Side effects of Vumerity that are different from Tysabri include flushing, nausea, vomiting, itching, albumin in the urine, redness, and indigestion/heartburn.

Side effects of Tysabri that are different from Vumerity include headache, tired feeling, joint or muscle pain, redness or irritation at the injection site, swelling hands/feet/ankles, changes in menstrual cycle, depression, painful menstrual cramps, and cold symptoms such as stuffy nose, sneezing, or sore throat.

Vumerity may interact with dimethyl fumarate.

Tysabri may interact with interferon, cyclosporine, sirolimus, tacrolimus, basiliximab, efalizumab, muromonab-CD3, mycophenolate mofetil, azathioprine, leflunomide, etanercept, and chemotherapy or radiation treatments.

Common side effects of Vumerity include:

• flushing,
• abdominal pain,
• diarrhea,
• nausea,
• vomiting,
• itching,
• rash,
• albumin in the urine,
• redness, and
• indigestion/heartburn

Common side effects of Tysabri include:

• headache,
• tired feeling,
• joint or muscle pain,
• redness or irritation at the injection site,
• swelling hands/feet/ankles,
• changes in menstrual cycle,
• stomach pain,
• diarrhea,
• skin rash,
• depression,
• painful menstrual cramps, or
• cold symptoms such as stuffy nose, sneezing, or sore throat.

Tell your doctor if you have side effects while Tysabri is being given or shortly after your treatment is finished (infusion reaction) including:

• chills,
• fever,
• flushing,
• nausea,
• dizziness, and
• chest pain.

Vumerity (diroximel fumarate) is an immunomodulator indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.

Tysabri (natalizumab) is a monoclonal antibody used in to treat relapsing forms of multiple sclerosis. Tysabri is also used to treat moderate to severe Crohn's disease in adults. Tysabri is usually given after other Crohn's disease medications have been tried without successful treatment of this condition.

Vumerity may interact with other medicines such as:

• dimethyl fumarate

Tell your doctor all medications and supplements you use.

Tysabri may interact with other medicines, especially those that may affect the immune system such as: interferon, cyclosporine, sirolimus, tacrolimus, basiliximab, efalizumab, muromonab-CD3, mycophenolate mofetil, azathioprine, leflunomide, etanercept, or chemotherapy or radiation treatments.

The starting dose of Vumerity is 231 mg twice a day, orally, for 7 days. The maintenance dose of Vumerity after 7 days is 462 mg (administered as two 231 mg capsules) twice a day, orally.

The recommended dose of Tysabri for multiple sclerosis or Crohn's disease is 300 mg intravenous infusion over one hour every four weeks.